Orthostatic hypotension
Drug research and approvals for orthostatic hypotension: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 25 studies of orthostatic hypotension are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 25
- Trials authorized in Canada: 5
- FDA orphan approvals: 2
- EU medicines: 0
Recruiting Now
Newest start dates first, of 25 recruiting on ClinicalTrials.gov ↗- NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes DiseaseNCT07398508 · Phase 1 / Phase 2 · Stephen G. Kaler · starts Aug 10, 2026
- Fainting Detection And Early Warning In Syncope Evaluation Study (ARISE)NCT07502599 · Not reported · Boston Scientific Corporation · starts Aug 6, 2026
- Autonomic Regulation of Blood Pressure and Heart Rate During Orthostasis and Exercise in Healthy and Hypertensive…NCT07482462 · Not reported · University Medical Centre Ljubljana · starts Oct 15, 2025
- Effects of Breathing Retraining Exercises in Pregnant Females With Postural Orthostatic Tachycardia Syndrome.NCT07579026 · Not applicable · Riphah International University · starts Aug 31, 2025
- Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System…NCT06831500 · Phase 1 / Phase 2 · Julien Bally · starts Jul 18, 2025
- Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's DiseaseNCT06920134 · Not applicable · Ecole Polytechnique Fédérale de Lausanne · starts Jul 3, 2025
- Blood Pressure Following Isometric Exercise in Inactive AdultsNCT06937164 · Not applicable · Canterbury Christ Church University · starts Apr 21, 2025
- Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord InjuryNCT06841198 · Not applicable · Kessler Foundation · starts Apr 1, 2025
- The STAND-UP StudyNCT07195903 · Not applicable · St. Francis Hospital, New York · starts Jan 23, 2025
- The Value of Near-infrared Spectroscopy and Blood Pressure Measurements in Estimating Future Fall Risk in Older AdultsNCT06714565 · Not reported · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · starts Dec 4, 2024
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 26, 2026 | Controlled co2 inhalation to increase blood pressure in neurogenic orthostatic hypotension: a proof-of-concept novel therapy studyCARBON DIOXIDE | GOVERNORS OF THE UNIVERSITY OF CALGARY | Ongoing |
| Jan 27, 2020 | A phase 3, 182-week, open-label, safety and tolerability study of td-9855 in treating symptomatic neurogenic orthostatic hypotension (snoh) in subjects with…AMPRELOXETINE (TD-9855) | THERAVANCE BIOPHARMA IRELAND LIMITED | Closed |
| Jun 24, 2019 | A phase 3, 22-week, multi-center, randomized withdrawal study of td¿9855 in treating symptomatic neurogenic orthostatic hypotension in subjects with primary…AMPRELOXETINE (TD-9855) | THERAVANCE BIOPHARMA IRELAND LIMITED | Closed |
| Feb 28, 2019 | A phase 3, 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of td-9855 in treating symptomatic neurogenic orthostatic…AMPRELOXETINE (TD-9855) | THERAVANCE BIOPHARMA IRELAND LIMITED | Closed |
| Dec 11, 2013 | Phoenix: a clinical study of patients with symptomatic neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapyDROXIDOPA | Chelsea Therapeutics, Inc. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Feb 18, 2014 | NORTHERATreatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic… | Lundbeck LLC | Approved |
| Sep 6, 1996 | AmatineTreatment of symptomatic orthostatic hypotension. | Takeda Development Center Americas, Inc. | Approved |
| May 9, 2023 | AmpreloxetineTreatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy | Theravance Biopharma Ireland Limited | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA